about
Reinventing diagnostics for personalized therapy in oncologyONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells.Preliminary safety and efficacy results of laser immunotherapy for the treatment of metastatic breast cancer patients.There is no association between microRNA gene polymorphisms and risk of triple negative breast cancer in a Chinese Han population.Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey.RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer.Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67.Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple negative breast cancer: a phase III study.Effect of anti-DR5 and chemotherapy on basal-like breast cancer.A single-nucleotide polymorphism in the 3'-UTR region of the adipocyte fatty acid binding protein 4 gene is associated with prognosis of triple-negative breast cancer.Adjunctive imprint cytology of core needle biopsy specimens improved diagnostic accuracy for breast cancerHyaluronan metabolism in remodeling extracellular matrix: probes for imaging and therapy of breast cancer.Adjuvant treatments for triple-negative breast cancers.Subtyping of breast cancer using reverse phase protein arrays.FZD7 has a critical role in cell proliferation in triple negative breast cancer.CIDE-3 interacts with lipopolysaccharide-induced tumor necrosis factor, and overexpression increases apoptosis in hepatocellular carcinoma.Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes.Efficacy of adjuvant chemotherapy with carboplatin for early triple negative breast cancer: a single center experience.Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy.Tumor xenograft modeling identifies an association between TCF4 loss and breast cancer chemoresistance.Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cells.Polymorphisms in and are associated with the survival of triple-negative breast cancer patients treated with taxane-based adjuvant chemotherapy
P2860
Q28391395-AD7BC5B8-2422-4683-9051-BAA981BB60CBQ33591623-F33CC28E-D824-4F95-902C-0D3DD13154C1Q33836906-0045D639-8DC9-4F11-B7A7-3D1D2188C1A1Q34653505-912B4822-1E9F-48F6-8135-B2470E2B2FA1Q35145663-C4AFE32E-955A-46E4-926F-DF3C852CC8C1Q35620241-3AD46949-DCEE-4273-A05E-720FB572FB64Q35889626-1142B972-CA55-4E9A-BDCD-1100750855EFQ36352501-FE954EFC-D646-41B6-A8A1-E7DEAE6568F3Q36731275-921EEF5E-BEE3-436C-99EA-8882612CB7B9Q37109912-CE3F6327-07E4-43C7-B4C9-8CACA10F14EAQ37128342-18A04341-1C3D-4CF8-BA41-C9C6C76A7DC0Q37832163-81131847-AC9F-4D3E-A118-C37EC7173D8AQ38046581-91E4A23C-4567-4C84-A3A0-68D65C30C285Q38268585-55201B52-3EE8-4548-A463-1EC6FC6F448FQ39550398-94815306-0B61-4151-A110-532D974454B2Q39642405-4A848657-EFED-4B0A-9488-21F7FABC0029Q42275833-675DDE4A-F667-4226-8D23-C821B09BDB85Q46251266-A558CCDD-2C46-4CC8-8452-0172CA3F4B3DQ49188143-99092F55-77A0-4A7C-BD8C-599F167AB694Q52318759-1265DF10-508A-4D58-8B9C-D8F7872E3169Q52583854-3AB65952-AC1E-43B6-A88B-5788E024D667Q57071024-788C2EF3-C01A-4370-876E-60505736EE86
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Adjuvant therapy of triple negative breast cancer.
@en
Adjuvant therapy of triple negative breast cancer.
@nl
type
label
Adjuvant therapy of triple negative breast cancer.
@en
Adjuvant therapy of triple negative breast cancer.
@nl
prefLabel
Adjuvant therapy of triple negative breast cancer.
@en
Adjuvant therapy of triple negative breast cancer.
@nl
P2093
P2860
P1476
Adjuvant therapy of triple negative breast cancer.
@en
P2093
Alvaro Moreno-Aspitia
Cathy A Andorfer
E Aubrey Thompson
Edith A Perez
P2860
P2888
P304
P356
10.1007/S10549-010-0736-Z
P407
P577
2010-01-22T00:00:00Z